Maintenance Guide · Updated March 2026

GLP-1 Microdosing for Maintenance: What It Is and My Experience on Mounjaro

GLP-1 microdosing maintenance is a growing strategy where patients use the lowest effective dose of medications like Mounjaro or Ozempic to keep weight off after hitting their goal. Studies show that up to two-thirds of people regain weight within a year of stopping GLP-1s entirely. I am testing a different approach.

I have been on Mounjaro for over a year now. My latest DEXA scan put me at 181.6 lbs and 21.9% body fat. My target is 165 lbs at 13-15% body fat, which means I still have work to do on the loss side. But I have already started thinking about what comes after, because I have seen too many people hit their goal, stop their medication cold turkey, and watch the scale climb right back up.

That is what led me to research GLP-1 microdosing for maintenance. And I want to share what I have found, what my plan is, and what the data actually says.

What GLP-1 Microdosing Maintenance Actually Means

Microdosing in this context does not mean taking a tiny fraction of a dose the way people talk about microdosing psychedelics. It refers to stepping down to the lowest effective dose of a GLP-1 medication after you reach your weight loss goal, rather than staying on the highest tolerated dose or stopping entirely.

For Mounjaro (tirzepatide), that might mean dropping from 10 mg or 15 mg down to 2.5 mg or 5 mg. For Ozempic (semaglutide), it could mean maintaining on 0.25 mg or 0.5 mg instead of the full 2.4 mg Wegovy dose.

The logic is simple. GLP-1 medications work on appetite regulation, insulin sensitivity, and gastric emptying. You do not necessarily need the maximum dose to maintain those effects once the heavy lifting of fat loss is done. A lower dose may be enough to keep hunger in check and prevent the metabolic rebound that causes regain.

This is not an FDA-approved protocol. There is no official “maintenance microdose” designation. But a growing number of prescribers and patients are experimenting with it, and the early results are promising.

Why People Regain Weight After Stopping GLP-1s

Before talking about the microdosing approach, it helps to understand what happens when you stop GLP-1 medications entirely.

The STEP 1 trial extension showed that participants who stopped semaglutide regained approximately two-thirds of their lost weight within one year. The SURMOUNT-4 trial for tirzepatide told a similar story. People who switched to placebo after 36 weeks of active treatment regained about half their weight loss within the following year.

This is not a willpower problem. GLP-1 medications change your hormonal signaling. They reduce ghrelin (the hunger hormone), slow gastric emptying, and alter reward pathways in the brain. When you remove the medication, those systems revert. Appetite returns. Satiety signals weaken. The body’s set point, which adjusted downward during treatment, starts pushing back up.

That is why the conversation has shifted from “when do I stop” to “what is the minimum effective dose to stay where I am.” If you want a full breakdown of the options after reaching your goal, I wrote a separate piece on GLP-1 exit strategies.

Full Dose vs. Microdose vs. Cold Turkey: A Comparison

Here is how the three main approaches compare for someone who has hit their weight loss target.

The sweet spot for most people is likely somewhere in the microdose column. You get meaningful appetite control and metabolic support at a fraction of the cost and side effect burden. But it requires finding your individual minimum effective dose, and that takes some experimentation.

How I Am Thinking About My Own Maintenance Plan

I am not in maintenance mode yet. At 181.6 lbs and 21.9% body fat, I still want to lose another 16-17 lbs of fat while preserving as much muscle as possible. I get DEXA scans every few months to track lean mass versus fat mass, because the scale alone tells you almost nothing useful. If you are not tracking body composition alongside your GLP-1 treatment, you are flying blind. I wrote about why that matters in my piece on exercise and muscle preservation on GLP-1s.

But here is my tentative plan for when I hit 165 lbs at my target body fat percentage.

Phase 1: Taper down (weeks 1-8). Instead of stopping Mounjaro abruptly, I plan to step down one dose level every 4 weeks. If I am at 10 mg, I will drop to 7.5 mg for a month, then 5 mg for a month.

Phase 2: Find the floor (weeks 9-16). Once I am at 5 mg, I will hold there for 4 weeks and see what happens to my weight, appetite, and DEXA numbers. If everything stays stable, I drop to 2.5 mg for another 4 weeks.

Phase 3: Maintenance microdose (ongoing). Ideally, I land on 2.5 mg as my maintenance dose. That is the lowest available Mounjaro dose. If I can hold my weight and body composition there, the plan works. If I start creeping back up, I bump to 5 mg and reassess.

Phase 4: Test the waters (optional). After 6+ months of stable maintenance on 2.5 mg, I might try spacing injections to every 10-14 days instead of weekly. Some patients and prescribers report success with this approach, though data is limited.

The key throughout all of this is measurement. Monthly weigh-ins are not enough. I will continue getting DEXA scans to watch lean mass and fat mass independently. If I lose muscle during the taper, that changes the calculus.

What the Research Says About Low-Dose GLP-1 Maintenance

There is no large-scale randomized controlled trial specifically studying GLP-1 microdosing for maintenance. That is the honest answer. But there is relevant data we can draw from.

The SURMOUNT-4 Trial

This trial enrolled patients who had already lost at least 5% of their body weight on tirzepatide over 36 weeks. They were then randomized to either continue tirzepatide at their current dose or switch to placebo. The placebo group regained about half their lost weight. The continued-treatment group kept losing or maintained.

What this tells us: staying on the medication matters. But the trial did not test what happens when you reduce the dose rather than stopping entirely. That is the gap in the evidence.

Real-World Prescriber Reports

A number of obesity medicine physicians have started publishing case series and clinical observations about dose reduction strategies. The general finding is that many patients can maintain their weight loss on lower doses than what they needed to achieve it. A patient who lost weight on 15 mg tirzepatide might maintain successfully on 5 mg or even 2.5 mg.

Dr. Spencer Nadolsky and others in the obesity medicine space have spoken publicly about titrating patients down to the lowest effective dose for maintenance. The approach is gaining traction in clinical practice even though the formal trial data has not caught up yet.

Pharmacokinetic Reasoning

Tirzepatide has a half-life of about 5 days. Semaglutide has a half-life of about 7 days. Even at lower doses, these drugs maintain steady-state concentrations with weekly dosing. A 2.5 mg weekly dose of tirzepatide still produces meaningful GLP-1 and GIP receptor activation. It is not nothing. It is a real pharmacological effect, just less intense than the full weight-loss dose.

The Cost Angle: Why Microdosing Makes Financial Sense

Let’s be practical about money. Staying on a high dose of a GLP-1 medication indefinitely is expensive.

Brand-name Mounjaro at the 15 mg dose runs $449/month through LillyDirect (Zepbound). Even compounded tirzepatide at full dose can cost $300-$400/month from most providers.

Drop to the 2.5 mg starting dose and the picture changes. LillyDirect prices Zepbound at $299/month for 2.5 mg. Some compounded providers charge as little as $99-$149/month for the lowest tirzepatide dose. Over a year, that is the difference between $5,400 and $1,200. Over five years of maintenance, you are talking about saving $20,000 or more.

If microdosing works for weight maintenance, and the early evidence says it can, then the financial argument alone is strong enough to try it. You do not need to stay on the maximum dose forever if a fraction of it keeps you stable.

Risks and Limitations of GLP-1 Microdosing

I do not want to oversell this. There are real risks and unknowns.

The dose might not be enough. Some people may need a higher maintenance dose than others based on their individual biology, degree of metabolic adaptation, and how much weight they lost. There is no universal maintenance dose. You have to find yours through trial and careful monitoring.

Rebound can be fast. If you drop too low too quickly, appetite can come back strong within 2-3 weeks. The taper needs to be gradual, and you need to be honest about what you are experiencing. “I feel fine” while gaining a pound a week for two months is not fine.

No long-term data. We do not have 5-year or 10-year data on low-dose GLP-1 maintenance. We are all, to some degree, figuring this out in real time. That is uncomfortable but also the reality of where obesity medicine stands today.

Muscle loss during the transition. If you relied on the appetite suppression to eat at a large deficit, and you reduce the medication without adjusting your training and protein intake, you risk losing lean mass during the transition. This is where strength training and adequate protein become non-negotiable.

Insurance and prescriber buy-in. Not every prescriber is comfortable with off-label dose reduction for maintenance. And insurance companies typically cover the dose your prescriber approves, not a lower one you prefer. You may need to advocate for yourself or find a prescriber who understands this approach.

The Bottom Line

GLP-1 microdosing for maintenance is not a proven protocol with an FDA stamp. It is a practical, evidence-informed strategy that is gaining ground among obesity medicine specialists and patients who want to keep their results without staying on maximum doses forever. The early clinical observations are encouraging. The pharmacology supports it. The cost savings are real. But it requires patience, careful monitoring, and a willingness to adjust. My plan is to taper my Mounjaro dose gradually once I reach my target, track everything with DEXA scans, and find the lowest dose that holds my weight and body composition steady. I will share the data as I go.

Frequently Asked Questions

What dose of Mounjaro is used for microdosing maintenance?

Most patients and prescribers start with the lowest available dose, which is 2.5 mg for Mounjaro (tirzepatide). Some maintain on 5 mg. The right dose depends on your individual response, how much weight you lost, and how your appetite and weight trend at each dose level. There is no single answer. You work down gradually and monitor the results.

Can I microdose Ozempic or Wegovy for maintenance too?

Yes, the same principle applies to semaglutide medications. Patients who lost weight on higher doses of Ozempic (1 mg or 2 mg) or Wegovy (2.4 mg) may be able to maintain on 0.25 mg or 0.5 mg. The half-life of semaglutide is longer than tirzepatide (about 7 days versus 5 days), which may offer slightly more flexibility with dosing intervals.

How long should I stay at my full dose before tapering down?

Most obesity medicine physicians recommend maintaining your goal weight for at least 3-6 months at your current dose before starting to taper. This allows your metabolic set point to stabilize somewhat. Tapering too early, while your body is still adjusting to its new weight, increases the risk of rebound weight gain.

Will my insurance cover a lower maintenance dose?

Coverage varies widely. Some insurance plans cover GLP-1 medications at any prescribed dose. Others only approve specific dose ranges or require step therapy documentation. If your prescriber writes the prescription for a lower maintenance dose with appropriate clinical justification, many plans will cover it. Talk to your prescriber and insurance company about your specific situation.

This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before changing your medication dose. ClearMetabolic may earn a commission through provider links on this page. See our full disclosure.

Related

Guides:

• GLP-1 Exit Strategy · Exercise and Muscle on GLP-1s · Cheapest GLP-1 Online
• Fat Loss vs Weight Loss · DEXA Scan Results · Mounjaro Dosage Guide

Medications: Mounjaro · Ozempic · Wegovy · Zepbound

Compare: All Providers · Best GLP-1 Programs · All Guides